CD22-specific CAR-T modalities represent clinically relevant interventions for relapsed acute lymphoblastic leukemia management requiring definitive multicenter validation, whereas novel CAR-T/HSCT convergence approaches demonstrate enhanced disease control metrics that necessitate precision toxicity countermeasures, molecularly-defined eligibility parameters, and multi-omics surveillance platforms aligned with 2025 clinical implementation frameworks. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.